Early GP Referrals Lead to Longer Survival, Earlier Diagnosis for Patients with Cancer
A recent study led by led by King ' s College London and Public Health England examined 1.4 million patients of cancer via the National Cancer Registry and found that early GP referrals led to longer survival rates for patients. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Larotrectinib Demonstrates Limited Benefit in Patients with NTRK Alterations
This data analysis suggested that larotrectinib is highly effective in patients with NTRK gene fusions, however offered minimal benefit in patients with other non-fusion NTRK alterations. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
COVID-19 May Be Associated with Novel Pulmonary-Specific Vasculopathy
Given that thrombotic risk is significantly affected by race, researchers suggested that these findings may indicate that pulmonary vasculopathy may contribute to the unexplained differences in racial susceptibility to COVID-19 mortality. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Medicaid Not Associated with Improved Survival in Patients with SCLC
These findings suggest that there are significant outcome inequalities for patients with small cell lung cancer which are relevant to the policy debate on Medicaid expansion under the Affordable Care Act. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Henry Adewoye, MD, on the Phase I Trial of COM701 in Advanced Solid Tumors
The study was presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020 and demonstrated encouraging preliminary antitumor activity with objective responses as a monotherapy and in combination with nivolumab. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Outcomes of Larotrectinib by Prior Therapy and Performance Status in TRK Fusion Cancer
Researchers analyzed pooled data from 159 patients enrolled in 3 larotrectinib trials to assess outcomes stratified by prior lines of therapy and ECOG performance status. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Phase I/II Trial To Evaluate Dual HER2 Combination Therapy in HR+, HER2+ Breast Cancer
The multi-center trial is comprised of 2 phases, with phase I determining the maximum tolerated dose of palbociclib and phase II determining the clinical benefit rate of treatment with anastrozole, palbociclib, trastuzumab, and pertuzumab. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Approves Niraparib for Advanced Ovarian Cancer
The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Adavosertib Induces Tumor Shrinkage in 30% of Patients with Uterine Serous Carcinoma
A recent clinical trial ’s results found that a targeted drug known as adavosertib caused tumors in nearly 30% of patients examined with uterine serous carcinoma, a hard-to-treat form of uterine cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Hope Rugo, MD, on the Accelerated Approval of Sacituzumab Govitecan-hziy
The breast cancer expert discussed the implications of this approval, as well as the data that led to the approval of sacituzumab govitecan-hziy. (Source: CancerNetwork)
Source: CancerNetwork - April 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Approves Additional Recommended Dose of Pembrolizumab in Adults
The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications. (Source: CancerNetwork)
Source: CancerNetwork - April 28, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Interim Results from Phase Ib/II CLASSICAL-Lung Study Show Promise in NSCLC
Updated interim results from the phase Ib/II CLASSICAL-Lung study showed promise for pepinemab in combination with avelumab in patients with advanced stage non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Early Results from the Phase Ia/b Dose Escalation Trial of CG-806 in CLL/SLL and NHL
The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for whom no other treatment options are available. (Source: CancerNetwork)
Source: CancerNetwork - April 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
ASCO Addresses Changes in Cancer Care Due to the COVID-19 Pandemic
The American Society of Clinical Oncology and its affiliate organization the Association for Clinical Oncology announced the results of a survey that focused on the changes in cancer care due to COVID-19. (Source: CancerNetwork)
Source: CancerNetwork - April 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
